Last reviewed · How we verify
BTRX-246040
At a glance
| Generic name | BTRX-246040 |
|---|---|
| Sponsor | BlackThorn Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation (PHASE2)
- Investigating the Protective Impact of LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans (PHASE2)
- BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations (PHASE2)
- BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |